Pediatric Blood & Cancer最新文献

{"title":"Homoharringtonine in Relapsed/Refractory Paediatric T-Cell Acute Lymphoblastic Leukaemia—A Case Series and a Report on the Use of In Vitro Drug Profiling","authors":"Pui Yung Grace Tong,&nbsp;Guanglan Lin,&nbsp;Kam Tong Leung,&nbsp;Xiaofan Zhu,&nbsp;Xiaoming Liu,&nbsp;Jingliao Zhang,&nbsp;Chi Kong Li","doi":"10.1002/pbc.31576","DOIUrl":"10.1002/pbc.31576","url":null,"abstract":"<div>\u0000 \u0000 <p>Paediatric relapse/refractory T-cell acute lymphoblastic leukaemia (T-ALL) is notoriously difficult to treat. This group of heavily pre-treated patients needs effective agents that can rapidly control the disease while not having significant toxicity. Homoharringtonine (HHT) has been widely used in children with acute myeloid leukaemia, but there is little information on T-ALL. In this case series, HHT, in combination with other agents, achieved good response in five paediatric patients with T-ALL. The in vitro drug profiling in one patient demonstrated clinical correlation with HHT activity. The study sheds light on the potential of precision medicine for patients with relapsed/refractory leukaemia.</p>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Communicating a Pediatric Leukemia Diagnosis to a Child and Their Family: A Qualitative Study Into Oncologists’ Perspectives","authors":"Petra Buursma,&nbsp;Sasja A. Schepers,&nbsp;Daniël Zwerus,&nbsp;Rima Alkirawan,&nbsp;Esther M. M. van den Bergh,&nbsp;Natasja Dors,&nbsp;Peter M. Hoogerbrugge,&nbsp;Martha A. Grootenhuis,&nbsp;Marijke C. Kars","doi":"10.1002/pbc.31564","DOIUrl":"10.1002/pbc.31564","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A pediatric cancer diagnosis is overwhelming and stressful for the whole family. Patient-centered communication during the diagnostic conversation can support medical and psychosocial adaptation to the disease. Treatment of pediatric leukemia has become increasingly complex and requires a specific skillset from clinicians in effectively conveying information to families. The objective of the current study was to gain insight in the experiences and perspectives of pediatric oncologists when communicating leukemia diagnoses to families.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Procedure</h3>\u0000 \u0000 <p>In this exploratory qualitative study, oncologists were eligible to participate for each diagnostic conversation between May 2022 and February 2023 of families participating in a larger study. Twenty-six semi-structed interviews with 16 oncologists were thematically analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Two interrelated conversational goals were identified: (i) informing the family about the illness, prognosis, and treatment; and (ii) creating trust and comfort for the family implying they are in the right place for maximal chance of survival. Oncologists experienced a challenge in balancing a high amount of information provision in a short timespan with simultaneously monitoring the (emotional) capacity and needs of the family to process information. Remarkably, oncologists commonly seem to rely on intuition to guide the family through the diagnostic conversation. They mentioned to sometimes postpone answering to family-specific informational needs and prioritized information they assume to be more helpful for the family at that time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>During diagnostic conversations, oncologists aim to convey information they assume supports the needs of the family. Future research should investigate how these communication strategies are perceived by families.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31564","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-Based Surgical Guidelines for Treating Children With Rhabdomyosarcoma","authors":"Abdelhafeez H. Abdelhafeez,&nbsp;Tea Reljic,&nbsp;Farina Klocksieben,&nbsp;Ambuj Kumar,&nbsp;Sharon Cox,&nbsp;Andrew M. Davidoff,&nbsp;Kudzayi Munanzvi,&nbsp;C. E. J. (Sheila) Terwisscha van Scheltinga,&nbsp;Ahmed Elgendy,&nbsp;J. Ted Gerstle,&nbsp;Bilal Qureshi,&nbsp;Abdulrasheed Nasir,&nbsp;Timothy B. Lautz,&nbsp;Amabelle A. Moreno,&nbsp;Amos Loh,&nbsp;Sajid Qureshi,&nbsp;Gordan M. Vujanić,&nbsp;Pablo Lobos,&nbsp;Sheena Mukkada,&nbsp;Simone Abib","doi":"10.1002/pbc.31541","DOIUrl":"10.1002/pbc.31541","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Surgery remains the cornerstone of treatment for rhabdomyosarcoma (RMS) in children. However, there is considerable variation in surgical management practices worldwide, highlighting the need for standardized Clinical Practice Guidelines (CPG).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The CPG development involved assembling a multidisciplinary group, prioritizing 10 key topic areas, conducting evidence searches, and synthesizing findings. Recommendations were voted on using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methodology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recommendations</h3>\u0000 \u0000 <p>The panel recommended regional lymph node evaluation for patients with paratesticular RMS who are more than 10 years old and extremity RMS. Other suggestions included pretreatment re-excision for incompletely resected RMS, preoperative radiation therapy for unresectable tumors, maintaining a 0.5 cm resection margin, and tumor bed marking with surgical clips. The panel also suggests resection of residual metastatic disease following chemotherapy, resection of relapsed disease, and the least invasive approach for managing patients presenting with obstruction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This CPG provides evidence-based surgical management recommendations for RMS that can be adapted to diverse resource settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard Versus Reduced Hydration to Improve Elimination of High-Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial","authors":"Cady Noda,&nbsp;Lindsey Gwaltney,&nbsp;Roy Sabo,&nbsp;Megan Lo,&nbsp;Matthew Schefft","doi":"10.1002/pbc.31566","DOIUrl":"10.1002/pbc.31566","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hydration and urine alkalinization are the mainstays for the prevention of methotrexate-induced nephrotoxicity. Current oncology protocols recommend pediatric patients who are administered high-dose methotrexate (HDMTX) to be aggressively hydrated with an alkaline solution, which may lead to overhydration. This pilot study sought to determine whether reduced posthydration results in a shorter time to methotrexate elimination without increasing adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective randomized controlled crossover study design of pediatric patients with acute lymphoblastic leukemia was performed. Patients were randomized to begin with standard or reduced volume intravenous fluids. Over the course of four cycles of HDMTX, patients alternated between the standard rate of 125 mL/m²/h and a reduced volume rate of 62.5 mL/m²/h. The primary endpoint was the time from the start of HDMTX to a serum methotrexate concentration less than 0.1 µmol/L.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 37 HDMTX courses were analyzed in 10 patients aged 1–17 years. The median time to methotrexate elimination was similar between the standard and reduced hydration regimens at 71.7 h (60.8–115.6 h) versus 72.9 h (59.9–132 h, <i>p</i> value = 0.6539). There was no difference in the change from baseline to maximum creatinine (10% vs. 18.9%, <i>p</i> value = 0.6566), maximum weight gain (0.7 kg vs. 0.4 kg, <i>p</i> value = 0.0967), or rates of severe mucositis between hydration regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Reduced posthydration appeared to be safe and provided similar time to HDMTX elimination. A multicenter study is indicated to confirm the use of reduced hydration to optimize supportive care in pediatric patients administered HDMTX.</p>\u0000 \u0000 <p><b>Trial Registration</b>: NCT03964259.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Inflammatory Diseases in Children With Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues","authors":"Caroline Vinit,&nbsp;Corinne Guitton,&nbsp;Mariane De Montalembert,&nbsp;Patricia Benhaim,&nbsp;Lahoueri Amor-Chelihi,&nbsp;Brigitte Bader-Meunier,&nbsp;Florence Missud,&nbsp;Isabelle Melki,&nbsp;Vincent Gajdos,&nbsp;Cécile Arnaud,&nbsp;Annie Kamden,&nbsp;Oussama Charara,&nbsp;Véronique Hentgen,&nbsp;Sylvie Nathanson,&nbsp;Coralie Bloch,&nbsp;Ulrich Meinzer,&nbsp;Pierre Quartier,&nbsp;Isabelle Kone-Paut,&nbsp;Loïc De Pontual,&nbsp;Luu-Ly Pham","doi":"10.1002/pbc.31563","DOIUrl":"10.1002/pbc.31563","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Systemic inflammatory diseases (SIDs) have been reported in patients with sickle cell disease (SCD), but clinical data in children are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To identify clinical and laboratory features at diagnosis of SID in children with SCD and to describe their evolution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from children with SCD and SIDs were retrospectively collected in a French multicenter study from 1991 to 2018. Information included clinical characteristics, inflammatory markers, autoantibodies patterns, treatments, and complications. Inflammatory marker levels were compared at SID diagnosis and at the last follow-up. Statistical analyses were performed using Cran R software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among a cohort of 3800 children with SCD, 43 SIDs were identified in 35 study participants: autoimmune liver disease (AILD, <i>n</i> = 13), inflammatory bowel disease (IBD, <i>n</i> = 7), juvenile idiopathic arthritis (JIA, <i>n</i> = 6), systemic lupus erythematosus (<i>n</i> = 4), autoimmune hemolytic anemia (<i>n</i> = 3), Sjögren syndrome (<i>n</i> = 1), histiocytic necrotizing lymphadenitis (<i>n</i> = 2), vasculitis (<i>n</i> = 2), myasthenia gravis (<i>n</i> = 1), sarcoidosis (<i>n</i> = 1), idiopathic inflammatory granulomatous uveitis (<i>n</i> = 1), mixed connective tissue disease (<i>n</i> = 2). Prevalence of SID was 0.9% in our cohort of children with SCD. The median time between initial symptoms and SID diagnosis was 10 (3–20) months, notably longer in children with JIA, IBD, and Sjögren syndrome. Sixteen patients (46%) exhibited hypergammaglobulinemia (&gt;20 g/L) at diagnosis. No significant differences were observed for other inflammatory parameters. Twenty-one children (60%) received systemic steroids and 13 (37%) biological therapies. Three patients (9%) underwent hematopoietic stem cell transplantation. Nine patients (26%) had severe infections; one died.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Delayed diagnosis was frequent due to overlapping clinical presentations between SCD and SID. Clinicians must be aware of warning signs associated with elevated inflammatory markers, hypergammaglobulinemia, or specific antibodies. Therapeutic strategies remain challenging.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts for PBC Volume 72, Supplement 1","authors":"","doi":"10.1002/pbc.31562","DOIUrl":"10.1002/pbc.31562","url":null,"abstract":"&lt;p&gt;Christian Michel Zwaan&lt;/p&gt;&lt;p&gt;Ped Oncologist Princess Máxima Center, Utrecht and Erasmus MC, Rotterdam, Netherlands&lt;/p&gt;&lt;p&gt;Despite impressive improvements in outcome in pediatric acute leukemias over the past decades, both in pediatric ALL as well as in AML, medical need still exists for relapsed/refractory cases. However, rather than treating relapse, our aims should focus on the prevention of relapse by further increasing the efficacy of upfront treatment. The third major goal is to reduce long-term side effects by replacing toxic therapy elements by less toxic but equally efficacious therapy elements.&lt;/p&gt;&lt;p&gt;In the past improvements were mainly achieved by finetuning risk classification and available chemotherapy. However, the afore mentioned aims can best be achieved by studying the introduction of various recently developed drugs into pediatric leukemia treatment, especially when characterized by a different mode of action addressing the biology of the disease, as well as a better safety profile. During the presentation I will review the development stage and available data for several of the more novel compounds described below, that may have entered or may enter treatment for newly diagnosed patients in the near future, as well as briefly touch upon regulatory incentives and the role of Accelerate.&lt;/p&gt;&lt;p&gt;For BCP-ALL, this mainly concerns the introduction of blinatumomab and inotuzumab ozogamicin (the latter recently received approval in Japan, based on data from the ITCC059 study combined with data from patients treated in Japan), as well as the recently developed menin inhibitor revumenib, which is mainly of relevance for KMT2A-rearranged (infant) ALL. Other menin inhibitors are also under development, such as ziftomenib and bleximenib.&lt;/p&gt;&lt;p&gt;Other targeted therapy options are mainly relevant in Philadelphia-chromosome positive leukemias, and in adult ALL the concept of chemo-free induction therapy is already under development consisting of combinations of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib or ponatinib, in combination with with steroids or blinatumomab, and challenging the need for SCT in this disease. Similar studies are in development for newly diagnosed/relapsed Ph+-ALL in children. Moreover, patients with ABL-class fusions are also eligible for addition of TKIs.&lt;/p&gt;&lt;p&gt;Introducing CAR T-cell therapy as an alternative to SCT is an attractive therapy approach to avoid the long-term toxicities of SCT especially in case of TBI, which is needed in ALL in the conditioning regimen based on the results of the FORUM trial. Also for T-cell ALL, newer therapy options are available including CAR T-cell therapy, for example the allogenic off-the-shelf, fractricide-resistant CD7-targeted CAR-T cell therapy studies in the WU-CART-007 study, or an autologous product expressing an anti-CD7 CAR, and an anti-CD7 protein expression blocker (PEBL), which prevented CAR T cell fratricide. Next to Kymriah, in Europe a registration ","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 S1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31562","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review of the Presentation, Treatment, and Outcome of Chronic Disseminated Candidiasis in Children With Cancer or Following Hematopoietic Cell Transplant","authors":"Emelia Eagling-Every,&nbsp;Shu Ki Tsoi,&nbsp;Hannah Walker,&nbsp;Gabrielle M. Haeusler","doi":"10.1002/pbc.31560","DOIUrl":"10.1002/pbc.31560","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic disseminated candidiasis (CDC) is a rare complication of immunosuppression. This review describes the presentation, management, and outcomes of CDC in pediatric patients with cancer or following hematopoietic cell transplant (HCT). PubMed, Embase, and Medline were searched identifying 32 studies, describing 95 cases of CDC. CDC occurred almost exclusively in patients with leukemia (91%), with only 5% occurring in lymphoma, 1% post HCT, and 3% in solid tumor. The most frequent presenting symptoms were fever (97%) and abdominal pain (45%), with lesions in liver in 63% and spleen in 54% (less common in kidney, lungs and skin/soft tissue). Of the 67 (71%) episodes with microbiological confirmation, <i>Candida tropicalis</i> (28%) was the most common causative species. Antifungal treatment durations varied from 14 days to 28 months. Additionally, 31 (33%) patients received an adjuvant therapy, the most common being corticosteroids. Mortality, directly attributable to CDC, occurred in nine (9%). There remains insufficient data to guide a unified approach to management.</p>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Likes and Hashtags: Exploring the Potential Relationship Between Social Media Use and the Emotional Wellbeing of Oncology Professionals","authors":"Scott Moerdler,&nbsp;Yufei Yan,&nbsp;Stavroula Chrysanthopoulou,&nbsp;Maura Barry,&nbsp;Elizabeth Henry,&nbsp;Tiffany Lucas,&nbsp;Ariela Marshall,&nbsp;Don S. Dizon","doi":"10.1002/pbc.31568","DOIUrl":"10.1002/pbc.31568","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To explore the potential relationship between social media (SoMe) and burnout or overall wellbeing within the field of oncology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>A cross-sectional study of adult and pediatric oncology professionals conducted using an anonymous electronic survey. The survey was disseminated through the Children's Oncology Group (COG) and the SWOG Cancer Research Network (SWOG) member listservs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The majority of pediatric and adult oncology professionals are not engaging on, with only 873/3000 (29%) using SoMe professionally. Use of SoMe was associated with statistically significant higher incidence of self-reported burnout and poorer self-reported work‒life integration (WLI). However, both groups reported the same degree of career satisfaction and choosing the same career/job again. SoMe users and non-users reported similar overall psychological distress, although the use of SoMe was associated with less severe psychological distress.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While SoMe users reported higher rates of burnout and poorer WLI compared to non-users, it was not accompanied by higher levels of psychological distress. Furthermore, there were no differences in career satisfaction. These misalignments require further study.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31568","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Striped Hair Colour Change on Tovorafenib in an 18-Year-Old Boy With a Brainstem Low-Grade Glioma","authors":"Nicolas André,&nbsp;Caroline Donzé,&nbsp;Gabriel Revon-Rivière","doi":"10.1002/pbc.31567","DOIUrl":"10.1002/pbc.31567","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143040703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ghosal Type Hematodiaphyseal Dysplasia—A Rare and Unusual Cause of Cytopenias","authors":"Sirisha Rani Siddaiahgari,&nbsp;Veena Akkineni","doi":"10.1002/pbc.31533","DOIUrl":"10.1002/pbc.31533","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}